Lunai Bioworks Inc.
For the period ended Jun 30, 2026. Filed Oct 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Oct 13, 2026
LNAI$0.16-30.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at June 30, 2026 and 2025
| June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash | $1,713,653 | $92,700 |
| Investment in equity securities | — | 387,851 |
| Prepaids and other assets | 322,740 | 566,081 |
| Total Current Assets | 2,036,393 | 1,046,632 |
| Property and equipment, net | 12,015 | 367,843 |
| OTHER ASSETS | ||
| Definite life intangible assets, net | 1,819,394 | 14,994 |
| Software platform, net | 107,896 | 143,000 |
| Trademarks, net | 3,090 | 8,000 |
| Goodwill | 5,963,000 | 5,963,000 |
| Operating lease right-of-use assets | — | 687,371 |
| Total Other Assets | 7,893,380 | 6,816,365 |
| TOTAL ASSETS | $9,941,788 | $8,230,840 |
| LIABILITIES | ||
| CURRENT LIABILITIES: | ||
| Accounts payable – trade | $12,389,609 | $12,555,839 |
| Accrued expenses | 5,019,389 | 5,843,069 |
| Other current liabilities | 179,366 | 378,282 |
| Contingent consideration liability | 40,000 | 630,000 |
| Convertible notes payable | — | 245,000 |
| Current portion of operating lease liabilities | 293,787 | 313,047 |
| Notes payable | 388,335 | 3,580,525 |
| Notes payable – related parties, net | 600,000 | 5,610,372 |
| Total Current Liabilities | 18,910,486 | 29,156,134 |
| NON-CURRENT LIABILITIES: | ||
| Operating lease liabilities, net of current portion | 56,248 | 424,547 |
| Total Non-Current Liabilities | 56,248 | 424,547 |
| Total Liabilities | 18,966,734 | 29,580,681 |
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 8 shares designated as Series B Convertible Preferred Stock, all of which were issued and outstanding at June 30, 2026; no shares issued and outstanding at June 30, 2025 | — | — |
| Common stock, par value $0.0001, 350,000,000 shares authorized, 4,615,503 shares issued and outstanding at June 30, 2026; 2,217,411 shares issued and outstanding at June 30, 2025 | 462 | 222 |
| Additional paid-in capital | 505,155,698 | 478,297,665 |
| Accumulated deficit | (514,025,049) | (510,462,570) |
| Accumulated other comprehensive (loss) | (156,057) | 10,814,842 |
| Total Stockholders’ Equity (Deficit) | (9,024,946) | (21,349,841) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $9,941,788 | $8,230,840 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.